US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ipsen S.A.

103.50

0.0000

Volume:- -

Turnover:- -

Market Cap:8.55B

PE:11.85

High:103.50

Open:103.50

Low:103.50

Close:103.50

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IPSEF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPSEF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEF\",,,,,undefined,":{"symbol":"IPSEF","market":"US","secType":"STK","nameCN":"Ipsen S.A.","latestPrice":103.5,"timestamp":1747425600000,"preClose":103.5,"halted":0,"volume":0,"delay":15,"floatShares":28092893,"shares":82647356,"eps":8.73222,"marketStatus":"Market Closed","change":0,"latestTime":"05-16 16:00:00 EDT Delay","open":103.5,"high":103.5,"low":103.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":8.73222,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747641600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":103.5,"volumeRatio":0.20955569791372636},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEF\",,,,,undefined,":{"symbol":"IPSEF","floatShares":28092893,"roa":"8.22%","roe":"8.93%","lyrEps":8.610451,"volumeRatio":0.20955569791372636,"shares":82647356,"dividePrice":1.56269,"high":103.5,"amplitude":0,"preClose":103.5,"low":103.5,"week52Low":103.5,"pbRate":"1.83","psRate":"2.14","week52High":132.5,"institutionHeld":0,"latestPrice":103.5,"eps":8.73222,"divideRate":0.015098,"volume":0,"delay":15,"ttmEps":8.73222,"open":103.5,"prevYearClose":125.37,"prevWeekClose":103.5,"prevMonthClose":103.5,"prevQuarterClose":110.53,"fiveDayClose":103.5,"twentyDayClose":103.5,"sixtyDayClose":120.55},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IPSEF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPSEF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532065605","title":"Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2532065605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532065605?lang=en_us&edition=fundamental","pubTime":"2025-05-01 00:00","pubTimestamp":1746028800,"startTime":"0","endTime":"0","summary":"Information relating to the holding of the Combined Shareholders’ Meeting of 21 May 2025 of Ipsen S.A.PARIS, FRANCE, 30 April 2025 - Ipsen  announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen  to be held on Wednesday 21May 2025 at 3:00 p.m.  at the Salons de l'Htel des Arts et Métiers, 9 bis avenue d'Iéna, 75116 Paris.The Shareholders will be asked to approve in particular the following resolutions:. The payment of a dividend of 1.40 per share for the 2024 financial year, the ex-date being set on 4 June 2025 and the dividend payment on 6 June 2025;Any shareholder may consult these documents at the Company’s headquarters.Ipsen is listed in Paris  and in the U.S. th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-formalities-making-available-consulting-160000653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEY","BK4007","IPSEF"],"gpt_icon":0},{"id":"2529647669","title":"Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2529647669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529647669?lang=en_us&edition=fundamental","pubTime":"2025-04-24 14:14","pubTimestamp":1745475240,"startTime":"0","endTime":"0","summary":"Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options. Patients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase . Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placebo. PARIS, FRANCE, 24 April 2025 Ipsen  will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver  congress as an oral presentation, on 10 May at 11.15 CET. For the first time data highlighting the potential of elafibranor in treating people living with primary sclerosing cholangitis  will be presented. PSC is a rare liver disease that currently has no approved treatment options.Patients on elafibranor also had stabilization i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-elafibranor-primary-sclerosing-cholangitis-061400283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","BK4183","ALT","ELF","LU0053671581.USD","IPSEY","BK4139","BK4007","BK4585","LU1878469433.USD","LU1242518857.USD","PBC","LU1242518931.SGD","LU0979878070.USD","BK4588","EC","IPSEF","BK4201","BK4599","LU0566484027.USD","PSC","GGT"],"gpt_icon":0},{"id":"2527235393","title":"Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2527235393","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527235393?lang=en_us&edition=fundamental","pubTime":"2025-04-16 12:57","pubTimestamp":1744779420,"startTime":"0","endTime":"0","summary":"Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.PARIS, FRANCE, 16 April 2025 - Ipsen , a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025.Ipsen is confirming financial guidance for full-year 2025:. Ipsen anticipates several key milestones across its portfolio in 2025, including:. The regulatory filing for tovorafenib was accepted by EMA for review in the European Union, marking an important step forward in the development of this potential treatment for pediatric low-grade glioma and reinforcing Ipsen’s commitment to innovation in rare and difficult-to-treat cancers.Ipsen announced on March 19th the successful completion of its inaugural Rated Public Bond of 500 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-delivers-strong-sales-first-045700973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEF","IPSEY"],"gpt_icon":0},{"id":"2527197677","title":"Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2527197677","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527197677?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:00","pubTimestamp":1744646400,"startTime":"0","endTime":"0","summary":"Monthly information relative to the total number of voting rights and shares composing the share capital. Total number of shares composing the share capital.  Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds .* Gross total= total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The Gross total is used as a basis for the calculation of threshold crossings.** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-march-2025-monthly-information-160000112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IPSEF","IPSEY"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPSEF\",params:#limit:5,,,undefined,":[{"date":"2025-06-04","symbol":"IPSEF","amount":1.4,"announcedDate":"2025-02-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749043800000,"name":"Ipsen S.A.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-06","payableDate":"2025-06-05","currency":"EUR","dateTimestamp":1749009600000,"payDate":"2025-06-06"},{"date":"2024-05-30","symbol":"IPSEF","amount":1.2,"announcedDate":"2024-02-08","type":"dividend","market":"US","newRecordDate":"2024-05-31","defaultRemindTime":1717075800000,"name":"Ipsen S.A.","recordDate":"2024-06-03","payableDate":"2024-05-31","currency":"EUR","dateTimestamp":1717041600000,"payDate":"2024-06-03"},{"date":"2023-06-02","symbol":"IPSEF","amount":1.2,"announcedDate":"2023-02-09","type":"dividend","market":"US","newRecordDate":"2023-06-05","defaultRemindTime":1685712600000,"name":"Ipsen S.A.","recordDate":"2023-06-06","payableDate":"2023-06-05","currency":"EUR","dateTimestamp":1685678400000,"payDate":"2023-06-06"},{"market":"US","date":"2022-10-26","symbol":"IPSEF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1666756800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-05-31","symbol":"IPSEF","amount":1.2,"defaultRemindTime":1654003800000,"name":"Ipsen S.A.","recordDate":"2022-06-02","payableDate":"2022-06-01","currency":"EUR","type":"dividend","dateTimestamp":1653969600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPSEF\",market:\"US\",,,undefined,":[{"executeDate":"2019-05-31","recordDate":"2019-06-03","paymentDate":"2019-06-04","value":1,"currency":"EUR"},{"executeDate":"2020-06-03","recordDate":"2020-06-04","paymentDate":"2020-06-05","value":1,"currency":"EUR"},{"executeDate":"2021-05-31","recordDate":"2021-06-01","paymentDate":"2021-06-02","value":1,"currency":"EUR"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-02","value":1.2,"currency":"EUR"},{"executeDate":"2023-06-02","recordDate":"2023-06-05","paymentDate":"2023-06-06","value":1.2,"currency":"EUR"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPSEF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0714,"buy":0.2857,"hold":0.5714,"sell":0.0714,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.5714,"analysts":14,"updateTime":1743566400000}}}